RICHMOND, Va., March 27, 2002 (PRIMEZONE) -- Biotech/Phase III Drug Stocks Forum:
John McCamant of The Medical Technology Stock Letter Will Keynote
the Event and Provide Biotech Investing Recommendations
Biotech companies will discuss prospects and strategies at the Biotech/Phase III Drug Stocks Forum on Wednesday, April 3. This virtual Forum, free to investors, is accessible over the Internet via www.informedinvestors.com from 9:00 a.m.-11:00 a.m. EST. Investors have the opportunity to hear directly from company executives and get their investment information straight from the source.
The Informed Investors Forum will have senior executives from Biomira, Inc. (Nasdaq:BIOM), Aastrom Biosciences, Inc. (Nasdaq:ASTM) and Genome Therapeutics Corporation (Nasdaq:GENE) speaking for approximately 30 minutes each with PowerPoint presentations. Investors are invited to email questions to executives. The forum will also be archived on www.informedinvestors.com, www.vcall.com and www.investorconference.com.
The keynote address will be delivered by John McCamant, editor of The Medical Technology Stock Letter (MTSL). MTSL is a source for analysis and advice about investing in Biotechnology companies. It was the top performing financial advisory newsletter over the past 5 years according to the December 12, 2001 issue of the Hulbert Financial Digest. In addition, Hulbert ranks MTSL in the top 5 performing newsletters over the past 15 years. Mr. McCamant has fourteen years of experience dealing exclusively in the Biotechnology sector, and his Biotech investing insight has been featured in such places as The Washington Post, Yahoo!Finance, Business Week, Reuter's, Worth, and on CNN and CNBC.
Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. In addition to completion of the multinational Phase III trial with THERATOPE(r) vaccine for the treatment of metastatic breast cancer, and a Phase II pilot study of THERATOPE(r) vaccine in colorectal cancer, Biomira is developing a portfolio of complementary vaccine candidates, including BLP25 vaccine, which is undergoing a 166-patient Phase IIb study in patients with metastatic lung cancer and a Phase II pilot study in patients with prostate cancer. Biomira's commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy. They will be represented by President and Chief Executive Officer Alex McPherson, MD, Ph.D.
Aastrom Biosciences, Inc. is engaged in the development of human cell therapy products intended for a broad range of medical applications, based on its patented process and device capabilities. The Company's lead cell therapeutic products under development include Dendricell products (DC-I and DCV-I) for the clinical-scale production of dendritic cells intended for the emerging cancer vaccine market. The Company is also developing its SC-I, CB-I and CB-II cell products for use in stem cell therapy, and its OC-I cell product for the restoration of bone tissue.
Genome Therapeutics Corp. is engaged in the commercialization of genomics-based drug discovery. Through the identification of genes and the characterization of the function of those genes, the Company is seeking to accelerate the discovery and development of products to treat and diagnose a number of diseases. The United States government has selected the Company to participate in a number of government sponsored gene discovery programs, including the Human Genome Project, and the Rat Genome Sequencing Program. The Company's depth of experience in the genomics field permits it to be a leader in creating industrial scale genomics tools for product development. Its tools include high-throughput sequencing, sequence finishing, bioinformatics, functional genomics, and assay development.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink family of companies serving self-reliant investors.
About WILink: Since 1992, WILink (www.wilink.com) has opened information channels between public companies and potential investors. WILink is an investor relations and investment services group that markets a range of services that help publicly traded companies and mutual funds attract and retain well informed investors, while providing investors with access to information to make well informed investment decisions. This year WILink will make more than 7 million investor introductions to over 4,200 corporate clients through services including The Annual Reports Service, The Fund Info Service, Vcall (www.vcall.com) Investor Conference (www.investorconference.com) and Informed Investors Forums (www.informedinvestors.com). These services provide investors free access to onsite and webcast investor events and company financial reports through WILink's relationships with over 220 leading financial media channels in 14 countries including The Wall Street Journal, Financial Times, Barron's and Yahoo!Finance. For companies and mutual funds, these services enable compliance with regulation fair-disclosure requirements and provide visibility with investors at the precise point investors are making decisions. WILink, Inc. a wholly owned subsidiary of WILink.com plc (WLK on The London Stock Exchange) began operations in Richmond, Va. in 1993.